ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
0,00%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,955
-0,06%
Bitcoin
64 517,21
-0,47%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) Actualités

GNPX Genprex Inc

2,05
-0,03 (-1,44%)
21 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Genprex Inc GNPX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,03 -1,44% 2,05 06:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,03 2,01 2,08 2,05 2,08
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/5/202414:31PRNUSGenprex to Present at the 2024 BIO International Convention
20/5/202422:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202414:31PRNUSGenprex Doses First Patient in Acclaim-3 Clinical Study of..
13/5/202414:31PRNUSGenprex Announces the Appointment of Jose A. Moreno Toscano..
09/5/202414:11EDGAR2Form 8-K - Current report
09/5/202400:08PRNUSGenprex Announces the Passing of its Co-Founder and Chief..
01/5/202414:31PRNUSGenprex to Present and Participate at Upcoming May Investor..
09/4/202414:31PRNUSGenprex Collaborators Report Positive Preclinical Data on..
03/4/202414:31PRNUSGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical..
02/4/202414:31PRNUSGenprex Collaborators Publish Positive Preclinical Data with..
22/3/202421:10PRNUSGenprex Announces Closing of $6.5 Million Registered Direct..
19/3/202418:24PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
19/3/202413:36PRNUSGenprex Announces $6.5 Million Registered Direct Offering..
12/3/202414:01PRNUSGenprex Receives Notice of Patent Grant for Korean Patent..
06/3/202415:18EDGAR2Form 8-K - Current report
06/3/202414:30PRNUSGenprex Collaborators to Present Positive Preclinical Data..
26/2/202414:45EDGAR2Form 8-K - Current report
21/2/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202414:15PRNUSGenprex Expands Nonclinical Programs into New Therapeutic..
06/2/202413:30PRNUSGenprex to Present at Upcoming BIO CEO & Investor Conference
05/2/202414:15EDGAR2Form 8-K - Current report
05/2/202413:30PRNUSGenprex Announces First Patient Dosed in Phase 2a Expansion..
02/2/202413:30EDGAR2Form 8-K - Current report
31/1/202415:00EDGAR2Form 8-K - Current report
31/1/202414:42PRNUSGenprex Announces 1-for-40 Reverse Stock Split Effective..
05/1/202422:17EDGAR2Form 8-K - Current report
05/1/202413:00PRNUSGenprex Provides Business Update and Outlook for 2024
18/12/202322:35EDGAR2Form 8-K - Current report
13/12/202322:50EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/12/202322:44EDGAR2Form 8-K - Current report
14/11/202317:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202321:19EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03/11/202321:16EDGAR2Form DEF 14A - Other definitive proxy statements
01/11/202312:30PRNUSGenprex to Present at BIO-Europe 2023 Conference
23/10/202323:01EDGAR2Form PRE 14A - Other preliminary proxy statements
23/10/202322:44EDGAR2Form 8-K - Current report
20/10/202313:30PRNUSGenprex to Host a Virtual Key Opinion Leader Event on..
04/10/202318:00PRNUSGenprex to Present Data on the Use of REQORSA® for the..
25/9/202322:20EDGAR2Form 8-K - Current report
21/9/202314:30GLOBEGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation..
20/9/202314:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
08/9/202322:20EDGAR2Form 8-K - Current report
07/9/202313:30PRNUSGenprex to Present at Upcoming September Investor Conference
01/9/202322:17EDGAR2Form 8-K - Current report
22/8/202313:30PRNUSGenprex Appoints Suzanne Thornton-Jones as Senior Vice..
21/8/202323:13EDGAR2Form 8-K/A - Current report: [Amend]

Dernières Valeurs Consultées

NASDAQ
GNPX
Genprex
BIT
I09596
IT0005562811 20240621 35...
LSE
10HH
Macquarie.31
LSE
LBY
USOTC
LKOLD
Lakes Blue Energy NL (PK)
LSE
RSE
Riverstone Energy
AMEX
RSST
Return Stacked US Stocks...
USOTC
SROYF
Sailfish Royalty (QX)
BIT
P1TY68
BNP Paribas Issuance
ASX
BHU
ASX
SNX
Sierra Nevada Gold
TSX
CXF
CI Canadian Convertivle ...
LSE
0QZK
Coca-cola
NYSE
IVN.RT.WI
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés